Question

I am a breastfeeding mother and i want to know if it is safe to use EINECS 205-838-2? Is EINECS 205-838-2 safe for nursing mother and child? Does EINECS 205-838-2 extracts into breast milk? Does EINECS 205-838-2 has any long term or short term side effects on infants? Can EINECS 205-838-2 influence milk supply or can EINECS 205-838-2 decrease milk supply in lactating mothers?

EINECS 205-838-2 lactation summary

EINECS 205-838-2 is dangerous in breastfeeding
  • DrLact safety Score for EINECS 205-838-2 is 7 out of 8 which is considered Dangerous as per our analyses.
  • A safety Score of 7 indicates that usage of EINECS 205-838-2 may cause toxic or severe side effects in breastfed baby.
  • Our study of different scientific research indicates that EINECS 205-838-2 may cause moderate to high side effects or may affect milk supply in lactating mother.
  • Our suggestion is to use safer alternate options rather than using EINECS 205-838-2 .
  • Usage of EINECS 205-838-2 is in contradiction to breastfeeding hence if it is must to use EINECS 205-838-2 and there is no better alternative available then breastfeeding shall be stopped permanently or temporarily.
  • Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Answer by Dr. Ru: About EINECS 205-838-2 usage in lactation

Drug is cleared from the body after 25-50 elimination half-life. Resuming breastfeeding is likely safe after 48 hours of pump-and-dump.

Answer by DrLact: About EINECS 205-838-2 usage in lactation

No information is available on the use of EINECS 205-838-2 during breastfeeding. Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy, especially alkylating agents such as EINECS 205-838-2.[1] The manufacturer recommends that breastfeeding be discontinued during EINECS 205-838-2 therapy and for 1 month after the last dose.

EINECS 205-838-2 Possible Effects in Breastfeeding

Some evidence indicates that EINECS 205-838-2 can increase serum prolactin.[2]

Alternate Drugs

Bendamustine
Carmustine(Dangerous)
Temozolamide
Dacarbazine(Dangerous)
Bendamustine
Carmustine(Dangerous)

Synonyms of EINECS 205-838-2

AI3-52216
BCNU
Bi CNU
BiCNU
Bischlorethylnitrosourea
Bischlorethylnitrosurea
Bischloroethyl nitrosourea
Bischloroethylnitrosourea
1,3-Bis(beta-chloroethyl)-1-nitrosourea
1,3-Bis(2-chloroethyl)nitrosourea
1,3-Bis(2-chloroethyl)-1-nitrosourea
Bis(2-chloroethyl)nitrosourea
Bis(2-chloroethyl)1-nitrosourea
BRN 2049744
Carmubris
Carmustin
Carmustina [INN-Spanish]
Carmustinum [INN-Latin]
CCRIS 810
FDA 0345
Gliadel
NCI-C04773
Nitrumon
NSC-409962
SK 27702
SRI 1720
NSC 409962
DTI 015
Becenum
Carmustina
Carmustinum
UNII-U68WG3173Y
HSDB 7761
gliadel wafer
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.